FDA Approves New Use for Breast Cancer Drug
6th Oct 2005, 19:59 GMT
Aromasin, an aromatase inhibitor, may now be used to treat early breast cancer in postmenopausal women with estrogen-sensitive breast cancer who have already taken another breast cancer drug, tamoxifen, for two to three years.
FDA Approves New Use for Breast Cancer Drug related news:
- FDA Approves Pfizer Request To Market Breast Cancer Drug ... — Pfizer
- Pfizer Cancer Drug Gets Wider Approval — Operations-Related News from StratCenter.com
- FDA Approves Pfizer's Aromasin for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women — Radiology News from StratCenter.com
- EXCLUSIVE: BREAST CANCER DRUG ON NHS — Mirror.co.uk - News - Top Stories
- Woman Wins Right To Breast Cancer Drug — Sky News Home: First for breaking news around the UK and the globe
- Women Wins Right To Breast Cancer Drug — Sky News UK: Brings you closer to the news across Britain
- FDA Approves BioGenex InSite(TM) HER-2/neu (CB11) Monoclonal AntibodyAntibody Aids in Breast Cancer Prognosis and Therapy Selection — mysan.de
- Breast cancer drug: Your views — BBC News | Have Your Say | UK Edition
- FDA Approves BioGenex InSite HER-2/neu Monoclonal Antibody — Pharmaceuticals News from StratCenter.com
- Breast cancer drug test: Your views — BBC News | Have Your Say | UK Edition
Latest news from WebMD Health Headlines:
- Treat Rheumatoid Arthritis Early
- Christmas Trees May Be Allergy Trigger
- Breast Cancer Depression Common
- Red Meat May Up Breast Cancer Risk
- Delays Plague Flu Vaccine Supply
- Heart Disease Deaths Show Racial Gap
- Flu Vaccine: Low Risk of Rare Disease
- Veterans' Colon Cancer Screening Up
- Experts Call for Speedier Heart Care
- Fat in Fish May Help Prevent Dementia